Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) shares traded down 3.1% during trading on Friday . The company traded as low as $22.58 and last traded at $22.62, with a volume of 498,183 shares changing hands. The stock had previously closed at $23.35.

Several analysts recently weighed in on the company. Jefferies Group restated a “buy” rating and set a $28.00 target price (up previously from $23.00) on shares of Supernus Pharmaceuticals in a research note on Thursday, August 4th. Piper Jaffray Cos. downgraded Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 target price for the company. in a research note on Monday, July 18th. Northland Securities downgraded Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 target price for the company. in a research note on Monday, July 18th. Finally, Zacks Investment Research downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Supernus Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $24.50.

The company has a 50 day moving average price of $21.45 and a 200 day moving average price of $17.19. The stock has a market capitalization of $1.12 billion and a P/E ratio of 46.29.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.05. The firm earned $50.40 million during the quarter, compared to the consensus estimate of $49.67 million. During the same quarter last year, the firm earned $0.03 earnings per share. The business’s revenue for the quarter was up 43.6% on a year-over-year basis. Analysts expect that Supernus Pharmaceuticals Inc. will post $0.67 earnings per share for the current fiscal year.

In other news, CFO Gregory S. Patrick sold 3,395 shares of the business’s stock in a transaction dated Thursday, July 14th. The stock was sold at an average price of $22.00, for a total value of $74,690.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Other hedge funds have recently modified their holdings of the company. Marshall Wace LLP purchased a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth approximately $2,345,000. Cornerstone Capital Management Holdings LLC. increased its stake in Supernus Pharmaceuticals by 15.2% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 123,600 shares of the specialty pharmaceutical company’s stock worth $1,662,000 after buying an additional 16,300 shares in the last quarter. Finally, New York State Common Retirement Fund increased its stake in Supernus Pharmaceuticals by 3.7% in the fourth quarter. New York State Common Retirement Fund now owns 205,981 shares of the specialty pharmaceutical company’s stock worth $2,768,000 after buying an additional 7,299 shares in the last quarter.

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.